{"id":200653,"date":"2024-12-02T21:25:20","date_gmt":"2024-12-03T03:25:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-cell-therapy-generates-long-lasting-remission-for-leukemia-patients"},"modified":"2024-12-02T21:25:20","modified_gmt":"2024-12-03T03:25:20","slug":"car-t-cell-therapy-generates-long-lasting-remission-for-leukemia-patients","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/12\/car-t-cell-therapy-generates-long-lasting-remission-for-leukemia-patients","title":{"rendered":"CAR T-Cell Therapy Generates Long-Lasting Remission for Leukemia Patients"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/car-t-cell-therapy-generates-long-lasting-remission-for-leukemia-patients2.jpg\"><\/a><\/p>\n<p>Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some advanced cancers that previously had no therapeutic options. Chimeric antigen receptor T-cell (<a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/car-t-cell-therapy\">CAR T-cell<\/a>) therapy is one immunotherapeutic approach that has recently garnered significant attention. In brief, CAR T-cell therapy involves removing a patient\u2019s immune cells, altering them in a laboratory setting to make them better primed to detect and kill cancer cells, and delivering the modified cells back to the patient.<\/p>\n<p>A recent study published in the <em><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2406526\">New England Journal of Medicine<\/a><\/em> shows exciting new evidence of the benefits of CAR T cell therapy. The study (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04404660\">NCT04404660<\/a>) tested the treatment modality called obecabtagene autoleucel (<a href=\"https:\/\/www.fda.gov\/vaccines-blood-biologics\/aucatzyl\">obe-cel<\/a>), a CAR T-cell therapy that recognizes CD19, a marker expressed on leukemia cells. Unlike other CAR T-cell modalities used to treat leukemia, obe-cel recognizes the CD19 marker with only \u201cintermediate affinity\u201d instead of the \u201chigh affinity\u201d recognition of comparable therapies. Researchers suspected the lower affinity associated with obe-cel would correlate with reduced adverse effects experienced by patients receiving other CAR T-cell therapies.<\/p>\n<p>The phase 1b-2 multicenter study, which included 153 adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), revealed promising results. Of the 127 patients who received at least one infusion of obe-cel, 77% experienced remission, with 55% achieving complete remission. The observed remission rates were significantly higher than expected, indicating notable efficacy of the treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunotherapies have shaped the cancer research space over the past decade, proving effective for the treatment of some advanced cancers that previously had no therapeutic options. Chimeric antigen receptor T-cell (CAR T-cell) therapy is one immunotherapeutic approach that has recently garnered significant attention. In brief, CAR T-cell therapy involves removing a patient\u2019s immune cells, altering [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-200653","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=200653"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/200653\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=200653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=200653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=200653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}